GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Institutional Ownership

Mesoblast (Mesoblast) Institutional Ownership : 9.46% (As of Apr. 29, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Mesoblast's institutional ownership is 9.46%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Mesoblast's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Mesoblast's Float Percentage Of Total Shares Outstanding is 82.76%.

Mesoblast Institutional Ownership Historical Data

The historical data trend for Mesoblast's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Institutional Ownership Chart

Mesoblast Historical Data

The historical data trend for Mesoblast can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 18.09 17.26 13.72 13.65 13.42 10.74 9.47 9.49 9.49 9.46

Mesoblast Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Mesoblast (Mesoblast) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Institutional Ownership
Comparable Companies
ASX:OPT ASX:IMM ASX:CUV ASX:CU6 ASX:BOT ASX:IMU ASX:PYC ASX:RAC ASX:DXB ASX:PIQ OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
MESO:USA LWB:Germany MSB:Australia
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Website
https://www.mesoblast.com
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.